Mylan’s recent trading activity
On June 25, Mylan (MYL) ended the trading day at a closing price of $38.11. On the day, MYL stock was trading ~29.7% higher than the 52-week low of $29.39 it reported on August 15, 2017.
Mylan stock was trading ~20.3% lower than the 52-week high of $47.82 it reported on January 23.
Currently, MYL stock is trading lower than its 50-day moving average of $39.12 and its 200-day moving average of $41. Over the last month, Mylan stock has fallen ~3.2%. Year-to-date, the stock has registered a fall of ~9.9%.
Major events that triggered Mylan’s recent stock activity
On June 14, MYL stock fell ~2.5% in premarket trading. It fell ~3.9% in after-hours trading on the previous day after the company reported that its Advair generic had again failed to receive FDA approval. For more details on this development, read FDA Rejects Mylan’s Generic Advair Again, Stock Falls.
On June 5, Mylan stock rose more than 7% and registered after-hours gains of ~4.5% on the previous day on the news of the FDA’s approval of its biosimilar to Amgen’s (AMGN) Neulasta after the market closed.
However, on May 11, Mylan received some commercial litigation–related investigative demand, which led the stock to fall ~1.2% in after-hours trading on the day. On May 9, the company’s stock had fallen 1% in premarket trading on the news of the addition of its Epipen product to the FDA’s drug shortages list. However, the stock recovered during the day and registered a rise of 4%.
Comparison with industry and market performances
Over the last year, Mylan has registered a fall of 2.4% in its stock price. In comparison, the healthcare industry (XLV) has reported a one-year return of ~4.1% as of June 26. As of June 26, Mylan’s peers GlaxoSmithKline (GSK), Pfizer (PFE), and Amgen (AMGN) have registered returns of -9.4%, 6.9%, and 6.7%, respectively, over the last year.
In the next article, we’ll discuss Mylan’s recent launch of its generic Angiomax injection.